Discriminating between latent and active tuberculosis with multiple biomarker responses.

We sought to identify biomarker responses to tuberculosis specific antigens which could 1) improve the diagnosis of tuberculosis infection and 2) allow the differentiation of active and latent infections. Seventy subjects with active tuberculosis (N = 12), latent tuberculosis (N = 32), or no evidence of tuberculosis infection (N = 26) were evaluated. We used the Luminex Multiplexed Bead Array platform to simultaneously evaluate 25 biomarkers in the supernatant of whole blood samples following overnight stimulation using the Quantiferon(®) Gold In-Tube kit. We defined the response to stimulation as the difference (within an individual patient) between the response to the pooled tuberculosis antigens and the negative control. IP-10 response was significantly higher in tuberculosis-infected (active or latent) subjects compared to the uninfected group (p < 0.0001). Among the 25 parameters, expression levels of IL-15 and MCP-1 were found to be significantly higher in the active tuberculosis group compared to the latent tuberculosis group (p = 0.0006 and 0.0030, respectively). When combined, IL-15 and MCP-1 accurately identified 83% of active and 88% of latent infections. The combination of IL-15 and MCP-1 responses was accurate in distinguishing persons with active tuberculosis from persons with latent tuberculosis in this study.

[1]  Tsutomu Kawabe,et al.  Evaluation of interferon-γ, interferon-γ-inducing cytokines, and interferon-γ–inducible chemokines in tuberculous pleural effusions , 2005 .

[2]  R. Joshi,et al.  Sensitivity of a Whole-Blood Interferon-Gamma Assay Among Patients with Pulmonary Tuberculosis and Variations in T-Cell Responses During Anti-Tuberculosis Treatment , 2007, Infection.

[3]  S. Ehlers,et al.  Interleukin‐15 mediates protection against experimental tuberculosis: A role for NKG2D‐dependent effector mechanisms of CD8+ T cells , 2006, European journal of immunology.

[4]  K. Hornik,et al.  Unbiased Recursive Partitioning: A Conditional Inference Framework , 2006 .

[5]  H. Dvorak,et al.  The negative tuberculin test: tuberculin, HIV, and anergy panels. , 1995, American journal of respiratory and critical care medicine.

[6]  D. Goletti,et al.  Detection of interleukin-2 in addition to interferon-gamma discriminates active tuberculosis patients, latently infected individuals, and controls. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  T. Kawabe,et al.  Evaluation of interferon-gamma, interferon-gamma-inducing cytokines, and interferon-gamma-inducible chemokines in tuberculous pleural effusions. , 2005, The Journal of laboratory and clinical medicine.

[8]  H. Kirchner,et al.  High level of discordant IGRA results in HIV-infected adults and children. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[9]  S. Niemann,et al.  Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. , 2008, American journal of respiratory and critical care medicine.

[10]  S.-S. Jung,et al.  Monocyte chemotactic protein-1 production in patients with active pulmonary tuberculosis and tuberculous pleurisy , 2003, Inflammation Research.

[11]  Christopher Dye,et al.  Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country , 1999 .

[12]  P. Hopewell,et al.  Advances in the diagnosis and treatment of tuberculosis. , 2006, Proceedings of the American Thoracic Society.

[13]  G. Kaplan,et al.  The expression of a gamma interferon-induced protein (IP-10) in delayed immune responses in human skin , 1987, The Journal of experimental medicine.

[14]  Delia Goletti,et al.  Is IP-10 an Accurate Marker for Detecting M. tuberculosis-Specific Response in HIV-Infected Persons? , 2010, PloS one.

[15]  Kristian Kofoed,et al.  CXCL10/IP-10 release is induced by incubation of whole blood from tuberculosis patients with ESAT-6, CFP10 and TB7.7. , 2007, Microbes and infection.

[16]  J. Granados,et al.  Joint Effect of MCP-1 Genotype GG and MMP-1 Genotype 2G/2G Increases the Likelihood of Developing Pulmonary Tuberculosis in BCG-Vaccinated Individuals , 2010, PloS one.

[17]  T. Barkham,et al.  Tuberculosis treatment effect on T-cell interferon-&ggr; responses to Mycobacterium tuberculosis-specific antigens , 2010, European Respiratory Journal.

[18]  P. Sen,et al.  Theory of rank tests , 1969 .

[19]  T. Bodmer,et al.  Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis , 2008, European Respiratory Journal.

[20]  Lloyd N. Friedman,et al.  Diagnostic standards and classification of tuberculosis. , 1991, The American review of respiratory disease.

[21]  H. Kirchner,et al.  Highly discordant T cell responses in individuals with recent exposure to household tuberculosis , 2008, Thorax.

[22]  Jaroslav Hájek,et al.  Theory of rank tests , 1969 .

[23]  J. Adams,et al.  IL-15 Links TLR2/1-Induced Macrophage Differentiation to the Vitamin D-Dependent Antimicrobial Pathway , 2008, The Journal of Immunology.

[24]  Gerhard Walzl,et al.  Host markers in Quantiferon supernatants differentiate active TB from latent TB infection: preliminary report , 2009, BMC pulmonary medicine.

[25]  Toru Mori.  Usefulness of interferon-gamma release assays for diagnosing TB infection and problems with these assays , 2009, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[26]  R. Adegbola,et al.  Decay Kinetics of an Interferon Gamma Release Assay with Anti-Tuberculosis Therapy in Newly Diagnosed Tuberculosis Cases , 2010, PloS one.

[27]  S. Nejentsev,et al.  MCP-1 promoter variant -362C associated with protection from pulmonary tuberculosis in Ghana, West Africa. , 2008, Human molecular genetics.

[28]  M. Selman,et al.  A functional promoter polymorphism in monocyte chemoattractant protein–1 is associated with increased susceptibility to pulmonary tuberculosis , 2005, The Journal of experimental medicine.

[29]  C. Dye,et al.  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. , 1999, JAMA.

[30]  S. Radhakrishna,et al.  The development of clinical tuberculosis following infection with tubercle bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of clinical tuberculosis in the Netherlands. , 1982, Tubercle.

[31]  P. Ravn,et al.  IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay , 2009, BMC Research Notes.